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Abstract
In the United States, mortality rates from pancreatic
cancer (PCa) have not changed significantly over the
past 50 years. This is due, in part, to the lack of early
detection methods for this particularly aggressive form
of cancer. The objective of this study was to use high-
throughput protein profiling technology to identify
biomarkers in the serum proteome for the early
detection of resectable PCa. Using surface-enhanced
laser desorption/ionization mass spectrometry, protein
profiles were generated from sera of 49 PCa patients
and 54 unaffected individuals after fractionation on an
anion exchange resin. The samples were randomly
divided into a training set (69 samples) and test set (34
samples), and two multivariate analysis procedures,
classification and regression tree and logistic regres-
sion, were used to develop classification models from
these spectral data that could distinguish PCa from
control serum samples. In the test set, both models
correctly classified all of thePCapatient serumsamples
(100% sensitivity). Using the decision tree algorithm, a
specificity of 93.5% was obtained, whereas the logistic
regression model produced a specificity of 100%.
These results suggest that high-throughput proteomics
profiling has the capacity to provide new biomarkers
for the early detection and diagnosis of PCa.
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Introduction
Since 1950, the annual incidence of pancreatic cancer
(PCa) in the United States has increased from 5.3 to
9.2 cases per 100,000 population. The number of new
cases of pancreatic adenocarcinoma diagnosed each year
(f27,000 cases) essentially equals the mortality rate from
this disease (f26,000 deaths) [1,2]. Although a number of
studies indicate that the risk for PCa of cigarette smokers is
more than twice that for nonsmokers, in general, there is
little evidence for other extrinsic (e.g., alcohol or coffee
consumption, occupational exposure to carcinogens, and
radiation exposure) risk factors [3–7]. Thus, it has been difficult
to define an ‘‘at-risk’’ population for PCa screening.
As a further complication, detection of adenocarcinoma at
an early, treatable stage is difficult because the disease lacks
specific symptoms. Early symptoms of pancreatic carcinoma
including weight loss, anorexia, epigastric discomfort, and back
pain are often nonspecific and vague, so diagnosis may be
considerably delayed [8,9]. Furthermore, primary tumors of the
pancreas are relatively inaccessible to detection by routine
physical examination. Modern technological advances includ-
ing ultrasonography, dynamic computed tomography (CT
scan), magnetic resonance imaging (MRI), angiography, en-
doscopic retrograde cholangiopancreatography (ERCP), and
endoscopic ultrasonography have certainly aided the diagnosis
and staging of pancreatic carcinoma [7,10]. These new tech-
nologies, however, have not materially influenced survival from
PCa [10]. Although a wide variety of tumor-associated antigens
have been evaluated as markers for screening and diagnosis
of PCa, most have proven ineffective due to their low sensi-
tivity and cross-reactivity with other tumors. Thus, the poor
prognosis of patients is primarily due to the fact that most
patients present, and are treated, in the terminal stage of the
disease.
Despite the efforts of many groups, tumor markers that are
specifically expressed in PCa have yet to be identified. Cur-
rently, the tumor markers carcinoembryonic antigen (CEA) and
CA19-9, and mutations in the oncogene Ki-ras have been
employed in the staging and diagnosis of pancreatic neo-
plasms [11]. It has been found, however, that CA19-9 is
effective in discriminating between PCa and chronic pancrea-
titis, but not between PCa and other digestive cancers [12].
Although the diagnostic accuracy of CA19-9 appears superior
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to that of other tumor markers currently available, these
findings are valid only for patients with advanced cancers
[11–17]. CEA, a membrane glycoprotein originally described
as a tumor-associated colon cancer antigen, is now widely
used in clinical practice as a tumor marker [18]. CEA and
other tumor markers appear to have far less sensitivity and
specificity than CA19-9 in PCa. Sensitivity and specificity for
CEA have been reported to range from 59% to 71% and from
63.9% to 66.4%, respectively [14,16]. Using an upper limit of
normal of 37 U/ml, assays for CA19-9 have been reported to
range from 79.4% to 89.2% sensitivity and from 72.5% to
90% specificity [14,16,17]. Using a higher cutoff of 1000 U/
ml, the specificity of CA19-9 approaches 100%; however, the
sensitivity decreases to 24.3% to 41% [16,17]. CEA is
normally present in the human embryo and is found only in
minute amounts in healthy adults; however, it can be highly
expressed by malignant cells throughout the gastrointestinal
tract, as well as tumor cells arising from diverse locations
such as the breast, ovary, and lung [11]. Thus, the clinical
utility of CA19-9 is viewed by some clinicians as most
valuable in patients presenting with signs and symptoms of
a chronic pancreatic disorder, rather than as a screening test
to detect PCa in asymptomatic individuals [15,17].
Detection of cancer-derived gene products from biologic
fluids is an important emerging approach to the diagnosis of
malignant diseases. Due to the lack of any specific or
sensitive diagnostic test for the early stages of PCa, there
is a critical need for tumor markers to aid in the early
detection of this disease. Recent advances in techniques
used to generate ‘‘fingerprints’’ of cancer cells and identify
proteins elicited by tumors based on mass spectrometry
have yielded new biomarkers for the early detection of
cancers [19–22]. In particular, surface-enhanced laser de-
sorption/ionization time-of-flight mass spectrometry (SELDI-
TOF MS) [23–25] has been successfully applied to the
identification of serum biomarkers for the detection of breast
[26], liver [27], ovarian [28,29], and prostate cancers [30,31].
The goal of this study, therefore, was to use high-throughput
SELDI-TOF MS to identify directly the signature of serum
proteins in patients with pancreatic tumors compared with
patients without malignancies. We expect that new bio-
markers, which can be developed for the detection of this
deadly disease at a treatable (resectable) stage, will be
discovered.
Materials and Methods
Sample Collection and Preparation
Whole blood (5 ml) was collected in a serum separator
tube (SST) from patients at the University of Arkansas for
Medical Sciences Hospital and Clinics (Little Rock, AR) using
a protocol approved by the institutional IRB. Specimens were
collected from PCa patients and individuals with no evidence
of PCa. A self-administered questionnaire was collected
from each patient pertaining to gender, age, smoking and
alcohol usage, and medical history. For the separation of
serum, the blood in the SST tube was allowed to clot for 15
minutes and then centrifuged for 10 minutes at 1500g. The
serum from the SST was then aliquoted into cryovials and
immediately frozen at 70jC. Serum samples from PCa
patients were obtained from the Biospecimen Core in the
Pancreas Clinic at the Mayo Clinic Rochester (Rochester,
MN). Samples processed by the Mayo Clinic Molecular
Genetics Laboratory were collected in an EDTA lavender
or ACD yellow top tube, centrifuged at 3000 rpm for 10
minutes, aliquoted into tubes, and frozen at 70jC. All
serum samples were labeled with a unique identifier to
protect the confidentiality of the patient. None of the samples
was thawed more than twice before analysis.
The mean age (± SD) of the PCa patients was 66.4 ± 12.2
vs 53.5 ± 15.7 years among the control patients (P < .0001).
Thirty (61%) of the 49 cancer patients were male, compared
to 15 (28%) of 54 control patients (P = .0006). The 103 serum
samples were randomly divided into two groups in a 2:1 ratio
to yield a training set comprised of 36 patients with no
evidence of PCa, designated as ‘‘normal,’’ and 33 patients
diagnosed with PCa and a test set comprised of 34 serum
samples from both normal (n = 18) and PCa (n = 16) patients.
Staging information was available on 45 of 49 PCa patients
with a distribution of one stage I, 12 stage II, 13 stage III, and
19 stage IV patients. Included in the self-administered med-
ical histories of the non-PCa samples were seven patients
with a history of other cancers (five multiple myelomas, one
chronic lymphoblastic leukemia, and one testicular cancer).
A quality control (QC) sample was also prepared by pooling
serum from eight healthy male and eight healthy female age-
matched individuals.
Serum Fractionation
To increase the detection of a larger number of peaks as
well as to alleviate signal suppression effects on lower-
abundance proteins from highly abundant proteins such as
albumin, serum samples were fractionated into six fractions
containing proteins separated roughly on the basis of their
isoelectric points. Serum samples were loaded onto each
well of a 96-well filter plate prefilled with an anion exchange
sorbent (Serum Fractionation kit; Ciphergen Biosystems,
Freemont, CA) and eluted in a stepwise pH gradient using
a BIOMEK 2000 liquid-handling robot as described by the
manufacturer. The fraction containing the flow-through plus
proteins eluted with pH 9 buffer, which yields themost protein
peaks on the IMAC surface (S.B., unpublished observation)
[34], was selected for analysis. Each serum sample was di-
luted 10-fold during fractionation in 50 mM Tris–HCl, pH 9,
containing 0.1% nonionic detergent.
ProteinChip Array Analysis
For analysis of fractionated sera, samples were further
diluted 1:5 in phosphate-buffered saline (PBS) and applied
in duplicate onto each well of a 192-well bioprocessor con-
taining 16-spot IMAC-30 chips (Ciphergen Biosystems) pre-
viously activated with 100 mM CuSO4. The bioprocessor
was sealed and incubated with the samples for an hour, with
vigorous agitation on a Micromix 5 platform shaker. A pooled
QC sample prepared in the same manner was applied to
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duplicate spots on each chip used in each experiment as a
reproducibility control. The excess sera mixtures were dis-
carded and the chips were washed three times with PBS.
The chips were then washed with deionized water, removed
from the bioprocessor, and air-dried for 20 minutes. A
saturated solution of sinapinic acid (0.5 ml) in 50% acetoni-
trile, 0.5% trifluoroacetic acid was applied to each spot on the
chip surfaces. The array surface was allowed to dry for 10
minutes before another application of 0.5 ml of the sinapinic
acid solution.
Data Acquisition
ProteinChip arrays were read by a PBS-II C mass ana-
lyzer (Ciphergen Biosystems) and the spectral data were
acquired using Ciphergen Biosystems’ ProteinChip software
version 3.1. The TOF spectra were generated by averaging
156 laser shots in the positive mode with a laser intensity of
180, detector sensitivity of 8, and a focus lag time of 782
nanoseconds. The data acquisition parameters were opti-
mized to detect peaks in the range of 2 to 20 kDa, as this
range contained the majority of the resolved protein/peptide
peaks. Mass accuracy was calibrated using the all-in-one
peptide and all-in-one protein molecular weight standards
(Ciphergen Biosystems).
Data Analysis
The serum samples were analyzed in two batches. Peaks
were baseline-corrected and the spectra were normalized by
total ion current (TIC), the sum of ion intensities between the
2 and 20 kDa mass range applying the normalization coef-
ficient of the initial set of samples analyzed to normalize the
second set. Spectra for which the normalization factors were
either > 2 or < 0.5 were discarded. Using Ciphergen Bio-
systems’ Biomarker Wizard tool available with the Protein
Chip software, peaks consistently present across a minimum
of 20% of the spectra with a signal-to-noise ratio z 2.5 and
present within a mass window of 0.3% were detected and
clustered in the set. Corresponding peaks were likewise
identified in the spectra from the second set of samples
using the clustering data from the initial set.
Univariate Analysis
For each peak, the median patient-averaged intensity
was calculated for the normal and cancer groups. The
difference in group medians was reported as a ratio, the fold
change, and assessed for statistical significance through the
Wilcoxon rank-sum test with t approximation. Multiple com-
parison adjustment of P values was through the Stepdown
Permutation procedure of Westfall and Young [32] using
100,000 random permutations of class labels. A peak was
deemed to show a statistically significant difference in group
medians if its multiple comparison-adjusted P value was less
than .05.
Reproducibility
To examine the uniformity of spectral data collected within
and between experiments, a sample of the QC serum was
spotted in duplicate on each chip. The resulting spectra were
normalized, and the intensities of each peak identified by the
Ciphergen Biosystems software were measured. To mea-
sure variation between spots within a chip, the Spearman
correlation was calculated for the two QC samples on each
chip and the median correlation was determined for the 10
chips used in the training set. For the interchip correlation, the
average intensities for the two QC samples per chip were
determined, the Spearman correlation was calculated for
each of five randomly selected pairs of chips used in the
training set, and the median correlation of the pairs was
reported.
Intracluster Correlation Analysis
After TIC normalization, a total of 164 useable spectra
was obtained from 103 patients, with 61 patients contributing
pairs of spectra and 42 patients contributing single spectra. It
was expected that SELDI peaks from spectra paired by
patient would show appreciable correlation of intensities.
To determine the amount of correlation, the paired spectra
were subjected to variance components analysis on a peak-
by-peak basis using a random effects model with ‘‘patient’’ as
the random effect. In this manner, the within-patient and
between-patient variance terms were obtained for each
peak. The intracluster correlation coefficient (ICCC) was
calculated as the ratio of the between-patient variance to
the sum of the variance terms. For the 37 peaks with an m/z
ratio between 2000 and 20,000, the ICCCs had a median
value (interquartile range) of 85% (79–89%). Because of the
high ICCCs, the paired spectra from each patient were
averaged together on a peak-by-peak basis for subsequent
logistic regression analyses.
Multivariate Logistic Regression Classification
In multivariate model development, a weighted logistic
regression was used, in which the 42 patients contributing
single spectra were given a weight of 1.00, whereas the 61
patients contributing the average of two spectra were given a
weight equal to 2 minus the median ICCC (about 1.15).
Weights were then multiplied by a constant so that their
sum would be equal to the sample size. Our approach to
developing a classification model was guided by the recog-
nition that the results of automated variable selection proce-
dures can depend heavily on how the patients are allocated
into training and test sets. We sought for our final model a set
of peaks that would be insensitive to such allocation effects.
To accomplish this, we developed our classification model in
several stages.
In stage 1, the 103 patients (49 cancer; 54 normal) were
randomly divided into a training set of 52 patients (25 cancer)
and a test set of 51 patients (24 cancer). This process was
repeated 10,000 times to generate 10,000 random divisions
of the patients into training and test sets.
In stage 2, logistic regression was applied to the training
set of each random division of stage 1, with SELDI peaks
chosen by forward selection under an entry threshold of 0.1,
and the resulting model was then applied to the test set of
that random division. The response variable was the cancer
versus normal classification, and the goal was to predict
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correctly the class of test set members. Cross-validation and
test set class prediction probabilities were recorded along
withmodel parameter estimates. In this manner, we collected
10,000 logistic regression models generated by forward
selection on randomly chosen training sets, and 10,000
associated classification probabilities for each patient, ap-
proximately half of which were test set class prediction
probabilities. The frequency of each peak’s incorporation into
a forward selection model was calculated, and the five most
frequently incorporated peaks (‘‘the five good peaks’’) were
singled out for further modeling in stage 3. Additionally,
probabilities of prediction into the correct class were summed
across all test set patients within a random division. Final
models whose sums of correct class prediction probabilities
were near themaximumof 51 showed three frequent patterns
of peak selection; the most frequent of these (‘‘the four-peak
pattern’’) was also singled out for further modeling in stage 3.
In stage 3, logistic regression using the five good peaks or
the four-peak pattern was applied without variable selection
to the training set of each random division of stage 1, and the
resulting model was then applied to the test set of that
random division. As in stage 2, the goal was to predict
correctly the class of test set members. Cross-validation
and test set class prediction probabilities were recorded
along with parameter estimates for models using the five
good peaks, and the same was done for models using the
four-peak pattern. In this manner, we generated a distribu-
tion of estimated parameter vectors for both model types,
and a distribution of classification probabilities for each
patient. For each model type, the probabilities of correct
class prediction were summed across all test set patients
within a random division for use in stage 4.
In stage 4, the sums of correct class prediction probabil-
ities were assigned fractional ranks under the ‘‘ties=high’’
rule; this was done separately for the four-peak-pattern
models, the five-good-peak models, and the forward selec-
tion models. Performance of the three types of models
across 10,000 random divisions was then compared visually
by plotting sums of correct class prediction probabilities
against their fractional ranks. To provide a second measure
of performance for the three types of models, each patient’s
test set probabilities for cancer prediction were averaged
together to give an average Prob(Cancer) based on the
number of times the patient appeared in 10,000 test sets.
Receiver-operating characteristic (ROC) curves were then
calculated for each type of model. The area under the curve
(AUC) was calculated and used to compare the three types
of models for average performance on 10,000 random
divisions of the data into training and test sets.
On the basis of stage 4 results, it was determined that
models based on the four-peak pattern, consisting of SELDI
peaks having median m/z ratios of 3966.8, 3983.1, 8951.7,
and 7787.2, were far more likely to classify well, regardless
of random allocation into training and test sets, when com-
pared to models based on either the five good peaks or
forward selection. To derive a final multivariate classification
model, the 103 patients (49 cancer) were divided randomly
one more time into a training set of 69 patients (33 cancer)
and a test set of 34 patients (16 cancer). The four-peak
pattern was trained on the training set and applied to the test
set, and sensitivities and specificities of class prediction were
calculated under resubstitution, cross-validation, and test set
classification. The likelihood ratio test was used to determine
whether it was necessary to covariate-adjust the final clas-
sification model for the age and gender imbalance between
cancer and normal patients.
Classification and Regression Tree (CART) Model
The Biomarker Pattern software (version 4.0.1; Cipher-
gen Biosystems) implements the CART statistical procedure
described by Breiman et al. [33] to build a decision tree that
can classify a sample set into a given number of groups.
Classification trees were developed using a variety of pre-
dictors (peaks) and program parameters to build trees. Tree
building was then repeated to yield the best prediction
success with the lowest error cost. The optimal tree was
produced using a Gini power of zero, a minimum parent node
size of four, a 10-fold cross validation, and univariately
significant peaks with a median intensity > 10 in either the
cancer or normal serum samples as the input predictors.
Results
Serum Protein Profiles
To begin to screen for potential serum biomarkers and
identify a unique signature of serum proteins for early
detection of resectable PCa using the SELDI-TOF MS
technique, sera from 49 PCa patients and 54 control patients
were fractionated by anion exchange chromatography. In
this study, proteins that eluted with pH 9 buffer (flow-through
+ fraction 1) were applied in duplicate to IMAC3 ProteinChips
(Ciphergen Biosystems) and bound proteins were detected
with a ProteinChip Reader after laser desorption/ionization.
After normalization, 164 spectra were compiled and mass
peaks with mass-to-charge ratios (m/z) between 2000 and
20,000 and a signal-to-noise ratio > 2.5 were identified,
clustered, and analyzed. As shown in Figure 1, differences
in protein profiles between serum samples collected from
PCa patients versus controls were readily detected using
SELDI-TOF MS.
ProteinChip Reproducibility
To examine the variation in data collection within and
between the ProteinChips used in these experiments, a QC
sample representing a pool of sera from age-matched male
and female control subjects was applied in duplicate to each
ProteinChip. For each of the 10 chips used in the initial
analysis, the Spearman correlation was determined for the
QC samples on each chip, resulting in a median intrachip
correlation of 0.89. To examine the interchip correlation, the
average intensities of the two QC spectra on each chip were
determined, and the Spearman correlation was calculated
for five randomly selected pairs of the 10 chips used in the
initial set. The median interchip correlation for the five pairs
was 0.95.
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Univariate Analysis
Of the 37 SELDI peaks with median m/z ratio between
2000 and 20,000, 20 showed a statistically significant differ-
ence (P < .05) in median intensities between the cancer and
control samples (Table 1). Table 1 shows the fold change of
increase or decrease, along with raw and adjusted P values.
An adjusted P value of zero means that the corresponding
raw P value was lower than any produced by chance from
100,000 random permutations of class labels. Eight of these
specific protein peaks were elevated in PCa serum samples
(1.66- to 2.24-fold, PCa versus normal) and 12 peaks were
higher in sera from unaffected individuals (1.96- to 10.86-
fold, control versus PCa).
Multivariate Logistic Regression Classification
Figure 2 shows the proportion of times each peak was
incorporated under forward selection into classification mod-
els trained on 10,000 randomly chosen training sets of 52
patients (25 cancer). Only the 25 most frequently selected
peaks are shown, although every peak was selected at least
once. Median m/z ratios (incorporation rates ± standard
errors of rate) for the five peaks with highest multivariate
usage are: 3966.8 (92.8% ± 0.26%), 3983.1 (65.6% ±
0.48%), 4309.4 (32.8% ± 0.47%), 8951.7 (21.0% ± 0.41%),
and 5592.5 (17.1% ± 0.38%). These five peaks became ‘‘the
five good peaks’’ of additional classification modeling. The
6th to 10th peaks (median m/z of 9157.9, 3902.2, 4479.5,
8620.7, and 7787.2) had usage rates ranging from 12.3% to
10.4%, the 11th to 25th peaks had usage rates ranging from
4.62% to 1.00%, and the 12 peaks not shown in the figure
had usage rates ranging from 0.90% to 0.12%. The two
predominant features of Figure 2 are: 1) the sharp but
smooth drop in incorporation rates from 90% to 10% for
the first 10 peaks, and 2) the discontinuity in the trend
between the 10th and 11th peaks. When the 10,000 forward
selection models were applied to their test sets, 128 yielded
sums of correct class prediction probabilities within 0.1 of the
maximum value of 51. The peaks at 3966.8 and 3983.1
appeared in all 128; additional peaks at 8951.7 and 7787.2
appeared in more than half. These four peaks were the 1st,
2nd, 4th, and 10th most frequently incorporated peaks under
forward selection; they became ‘‘the four-peak pattern’’ of
additional classification modeling.
In additional classification modeling, the same 10,000
randomly chosen training sets were used to train classifica-
tion models containing either the five good peaks or the four-
peak pattern; the resulting models of each type were then
applied to their test sets to obtain class prediction probabil-
ities. For each test set and model type, the probabilities of
prediction into the correct class were summed across
patients, and the sums given fractional ranks. For each
patient, the probabilities of prediction into the cancer class
were averaged across test sets in which the patient ap-
peared, and the average probabilities were used to generate
ROC curves. Figure 3 shows the results of plotting sums of
Figure 1. Difference in SELDI spectra between normal and cancer serum samples. Upper panel: A portion of spectra from normal and PCa serum samples is
depicted as tracings in GelView (darker shades indicate higher mass peak intensities). Lower panel: An expanded portion of tracings from a PCa patient serum and
an unaffected individual is displayed, highlighting the differences in mass ions detected in the two patient populations.
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probabilities against their fractional ranks for the forward
selection models, the five-good-peak models, and the four-
peak-pattern models. The sum of probabilities per test set
can be interpreted as the expected number of correctly
classified patients in that test set; it therefore has a maxi-
mum value of 51. Under forward selection, 128 models
(1.28%) yielded an expected number within 0.1 of the
maximum value, whereas 9382 models (93.82%) yielded
an expected number below 49.9. Using the five good peaks,
144 models (1.44%) yielded an expected number within 0.1
Table 1. Significant Peaks by Univariate Analysis.
m/z Median Cancer Median Normal Cancer Effect Fold Change Raw* WRS P values Adjustedy P values Peaks Used
CART LR
3,276.1 0.488 1.948 Down 3.99 1.31E08 0
3,902.2 2.583 11.608 Down 4.49 2.45E20 0 X
3,966.8 3.291 25.679 Down 7.80 3.58E23 0 X X
3,983.1 1.830 15.466 Down 8.45 5.93E16 0 X X
4,295.4 1.721 18.692 Down 10.86 3.72E19 0
4,309.4 3.341 6.560 Down 1.96 4.43E05 0.00122
4,479.5 4.603 2.492 Up 1.85 5.04E05 0.00126
4,651.3 1.105 7.629 Down 6.91 1.04E12 0
5,592.5 0.210 1.461 Down 6.95 6.94E12 0
6,453.2 2.146 5.868 Down 2.73 0.0026 0.04274
6,648.1 6.124 18.273 Down 2.98 0.00032 0.00649
7,487.2 0.867 2.485 Down 2.87 5.91E11 0
7,787.2 1.437 4.125 Down 2.87 2.55E07 0.00003 X
8,620.7 16.195 7.768 Up 2.08 5.94E08 0.00001 X
8,951.7 29.137 15.360 Up 1.90 1.37E08 0 X X
8,966.2 15.177 7.188 Up 2.11 1.88E09 0
9,157.9 4.067 1.816 Up 2.24 2.83E11 0
11,498.4 0.354 0.213 Up 1.66 0.0026 0.04274
11,654.9 0.377 0.178 Up 2.12 0.00069 0.01349
11,711.9 0.393 0.215 Up 1.83 0.00071 0.01349
*Wilcoxon rank-sum test with t approximation.
yP values adjusted for multiple comparisons using stepdown permutation procedure [32].
Figure 2. Rate of incorporation into multivariate logistic classification models. The rate of incorporation was based on 10,000 random divisions of the data from 52
patients into training and test sets of approximately equal size. Each training set was used to develop a classification model via multivariate logistic regression using
forward selection with an entry threshold of P = .10. The incorporation rate for each peak is thus the proportion of times it was selected into 10,000 multivariate
classification models trained on random samples of half of the data. Only the 25 most frequently selected peaks are shown.
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of the maximum value, whereas 7041 models (70.41%)
yielded an expected number below 49.9. Using the four-
peak pattern, 3280 models (32.80%) yielded an expected
number within 0.1 of the maximum value, and only 3702
models (37.02%) yielded an expected number below 49.9.
Figure 4 shows the ROC curves generated from the aver-
age of cancer prediction probabilities for each patient when
they appeared in a test set. The AUCs are 0.9845 for the
forward selection models, 0.9962 for the five-good-peak
models, and 0.9996 for the four-peak-pattern models; an
AUC of 1.0000 would denote a correct classification of
every patient in every one of their appearances in a test
Figure 3. Plots of sums of probabilities against their fractional ranks for the forward selection models. The results of plotting sums of probabilities against their
fractional ranks for the four-peak-pattern (solid line), five-peak-pattern (dashed line), and forward selection (dotted line) models. The sum of probabilities per test
set can be interpreted as the expected number of correctly classified patients in that test set; it therefore has a maximum value of 51.
Figure 4. ROC curves generated from the average of cancer prediction probabilities for each patient. ROC curves generated from the average probability of cancer
based on each patient’s appearances in 10,000 random test sets. The AUC for the four-peak-pattern models (solid line) is 0.9996, for the five-peak-pattern models
(dashed line) is 0.9962, and for the forward selection models (dotted line) is 0.9845.
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set. These results indicate that models generated from
the four-peak pattern tend far more often to classify test
set patients correctly, compared to models generated from
either the five good peaks or from forward selection on all
37 peaks.
To derive parameter estimates for the final logistic re-
gression classification model, the 103 patients were random-
ly divided one more time in a 2:1 ratio, so that the training set
had 69 patients (33 cancer) and the test set had 34 patients
(16 cancer). The training set was then subjected to logistic
regression using the four-peak pattern, and the resulting
model was then tested on the test set. Table 2 shows the
parameter estimates and classification rule for the four-peak-
pattern model trained on this particular training set, and
Table 3 shows the sensitivity and specificity for the classifi-
cation rule under resubstitution, cross-validation, and test set
prediction. In additional analysis (not shown), we studied
whether the confounding of cancer with age and gender in
this data set would require their addition as covariates to the
final classification model. We resubjected the training set to
logistic regression using the four-peak pattern augmented
with age and gender, and then used the likelihood ratio test to
compare the augmented model to the model of Table 2. The
comparison yielded a P > .999, strongly suggesting that
covariate adjustment for age and gender is not needed.
CART Analysis
The Biomarker Patterns software (Ciphergen Biosys-
tems) was used to identify a subset of mass peaks that
could discriminate the patient sera. Initially, all 20 of the
significant peaks identified by univariate analysis were eval-
uated as potential predictors using 111 spectra derived from
the 69 serum samples initially used in the same training set
used for the final logistic regression classification model.
Each split was then rank-ordered on the basis of the quality-
of-split criterion using the Gini rule (a measure of how well
the splitting rule separates the classes contained in the
parent node) [33]. Once a best split was found (e.g., node
1 in Figure 5), the algorithm repeated the search process for
each child node, continuing recursively until further splitting
was impossible or stopped. After the maximal tree was
grown, smaller trees were examined by pruning away
branches of the maximal tree, using cross-validation to
estimate the error rate of the subtrees. Following this same
procedure, a variety of possible predictors (peaks) and
program parameters were used to build an optimal classifi-
cation tree that yielded the lowest error cost. The optimal tree
(i.e., the tree with the lowest error cost) was generated using
the eight peaks with significant differences between the
cancer and normal groups that had a median intensity > 10
in either the cancer or normal group as the input predictors
(Table 1). From these initial eight peaks, five peaks were
identified, which discriminated the control and PCa sera
(Figure 5) with a sensitivity of 96.5% and a specificity of
100% (Table 3). Three of these five peaks (m/z = 3966.8,
3983.1, and 8951.7) had also been identified in the multivar-
iate logistic regression model as the best discriminators of
PCa versus non-PCa sera (Table 1). Using a 10-fold cross-
validation of the training set, a sensitivity of 93% and a
specificity of 94.4% were obtained (Table 3). The decision
matrix embodying the classification tree (Figure 5) was then
applied to a test set of 53 spectra, representing 34 serum
specimens. All of the 22 PCa spectra and 29 of 31 normal
spectra were correctly classified, yielding a sensitivity and
a specificity of 100% and 93.5%, respectively.
Group Comparisons
The intensities of the peaks used in the CART and logistic
regression models were plotted and compared for individual
spectra representing the control patients and PCa patients
for whom staging information was available (Figure 6). The
scatter plots reveal that the range of peak intensities for any
of the individual peaks used to classify normal versus cancer
overlaps between the normal samples and the PCa samples
regardless of tumor stage. This overlap may reflect the
historical failure to find a single marker that changes in serum
as pancreatic tumors (or most other tumors) progress, and
supports the notion that the successful discovery of new
diagnostic biomarkers will require a panel of markers whose
changes in serum levels are more subtle.
Discussion
Currently, there are no methods for the early detection of
PCa. As a consequence, patients frequently present with
Table 2. Logistic Classification Model.
Parameter Name Estimate of
Coefficient
Likelihood Ratio Test of Hnull: All
Coefficients Equal Zero
Intercept 173.8 Likelihood ratio
chi square analysis
95.5993
MZ03966.8 23.0981
MZ03983.1 18.3736 Degrees of freedom 4
MZ08951.7 6.9714
MZ07787.2 46.2511 P value < .0001
Classification equation: Score = 173.8 + (23.0981*MZ03966.8) +
(18.3736*MZ0983.1) + (6.9714*MZ08951.7) + (46.2511*MZ07787.2),
where ‘‘Score’’ equals the natural logarithm of the odds of being cancer, and
‘‘MZ0xxxx.x’’ represents the intensity of the peak with the indicated m/z ratio.
Classification decision rule: If Score is positive, classify as cancer; otherwise,
classify as normal.
Table 3. Classification Results.
CART Logistic Regression
Correct/Total Percent Correct/Total Percent
Training set resubstitution results
Sensitivity 55/57 96.5 33/33 100
Specificity 54/54 100 36/36 100
Training set cross-validation results
Sensitivity 53/57 93.0 31/33 93.9
Specificity 51/54 94.4 35/36 97.2
Classification results for test set
Sensitivity 22/22 100 16/16 100
Specificity 29/31 93.5 18/18 100
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metastatic disease for which treatment is palliative rather
than curative. The most widely used tumor-associated anti-
gen for PCa, CA19-9, lacks adequate sensitivity and spec-
ificity and has limited utility as an indicator of early, localized
pancreatic disease. As early surgery is the only curative
intervention, there is a lingering need for better biomarkers
for the early detection of resectable PCa. Recently, the use
of SELDI-TOF MS for high-throughput profiling of serum
proteins has gained attention as a facile method to identify
panels of peptides and proteins that may be indicative of
early disease for several cancers [26–31]. Using a similar
approach, we have identified protein profiles in this study that
were capable of distinguishing sera of PCa patients from
unaffected individuals.
A total of 103 serum samples, representing 49 patients
with PCa and 54 individuals with no evidence of PCa, were
used to prepare protein profiles. To enhance the selection of
mass peaks with biologic relevance, spectral data were
analyzed by two independent multivariate methods (CART
and multivariate logistic regression). In each of these meth-
ods, a small subset of mass peaks that could readily distin-
guish the two sample populations was identified. A
comparison of the features selected by these two models
indicates that three of the peaks are used as primary
discriminators in both models (m/z = 3966.8, 3983.1, and
8951.7) (Table 1). This observation provides confidence that
these mass peaks are disease-relevant classifiers.
The manner in which the aforementioned mass peaks
found their way into our logistic regression final model gives
us additional confidence that they are disease-relevant clas-
sifiers. The process by which these peaks were identified
was similar to the Bootstrap selection procedure described
by Koopmann et al. [34], but was computationally more
intensive. We divided the data randomly 10,000 times into
training and test sets of approximately equal size. We then
subjected the 10,000 random training sets to logistic regres-
sion with forward selection on all 37 mass peaks to see how
often each peak would be chosen for incorporation into a
Figure 5. CART decision tree. Spectra from 69 serum samples were used as a learning set to generate a decision tree to distinguish between serum obtained from
PCa patients and serum from unaffected individuals. Decision nodes (hexagons) represent individual mass peaks (m/z) and a threshold criterion for traversing the
tree (top to bottom). Terminal nodes (squares) determine whether a sample is classified as normal or PCa. One PCa sample (represented by two spectra) was
misclassified in the training set belonging to terminal node 4.
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multivariate classification model. We found that every peak
was chosen at least once (the minimum was 12 times), that
no peak was chosen 100% of the time (the maximum was
92.79%), and that the frequency of choice dropped sharply
from the maximum (Figure 2). These findings demonstrate
that the result of training a classification model under an
automated variable selection procedure can be markedly
sensitive to the particulars of a training-versus-test set
division. In an effort to avoid such allocation artifacts, we
chose two promising peak patterns to compare against
forward selection for their average performance as multivar-
iate logistic regression classifiers. The peaks at m/z =
3966.8, 3983.1, and 8951.7 were common to both patterns.
For each pattern, we trained its classifier on the random
training sets, tested the results on the corresponding random
test sets, and estimated the expected number of correct
classifications per test set for comparison. When the results
for all 10,000 random test sets were plotted (Figure 3), it was
clear that both patterns outperformed the set of models
trained under forward selection. One pattern in particular,
containing the three mass peaks above plus one other, did
extremely well. From test set results, we also computed the
average probability of being classified as cancer when in a
test set for each patient under each peak pattern. Because
this average probability per patient is based on that patient’s
appearance in about half of the 10,000 random test sets, it
Figure 6. Group comparisons. Scatter plots of peak intensities from individual spectra of control serum (Nml) or sera from stage II (including one stage IB patient),
III, and IV PCa patients for the eight peaks used in the logistic regression and CART classification models. Horizontal bar represents median peak intensities for
each group.
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can be interpreted as an estimate of the patient’s fractional
class membership that is independent of the particulars of
training-versus-test set division, but still sensitive to the
peak pattern and/or selection procedure used in the classi-
fier. That interpretation should carryover to ROC curves
constructed from such average probabilities (Figure 4).
These considerations add to our confidence that the peaks
we have identified have a classification proficiency that is
biologically real and not an artifact of the choice of samples
for the training set.
After cross-validation of the models, the spectra produced
from the remaining 34 serum samples (16 PCa and 18
controls) were used as an independent test set to validate
the two classification models. Both models correctly clas-
sified all of the PCa samples (100% sensitivity). The spe-
cificities determined for the two classification schemes
were 93.5% for the CART model and 100% for the logistic
regression model (Table 2). Included in the ‘‘normal’’ serum
samples were seven patients with histories of other malig-
nancies; thus, these models were able to correctly distin-
guish changes in serum protein profiles in PCa patients from
other malignancies. Although the number and types of other
malignancies included in this study are very limited, the
results provide promise that this approach will be useful for
specifically distinguishing PCa from other neoplasms based
on a panel of serum biomarkers.
An examination of the mass peaks utilized by the two
classification models reveals both increases and decreases
in their median intensities when comparing the PCa serum
proteome to that of the control serum (Table 1). This sug-
gests that specific circulating serum proteins/peptides can be
either elevated or diminished as a consequence of the
disease state, and that these changes may be exploited to
detect the presence of the tumor. Because the blood pro-
teome perfuses the diseased organ, proteins abnormally
shed by the tumor may add to the serum proteome, or
enhanced proteolytic-degrading activities of the tumor may
reduce specific serum protein levels [19]. A similar pattern of
overexpression and underexpression of peptide/protein
masses was observed by Adam et al. [30] in the serum
protein fingerprint of their prostate cancer study. The identi-
fication of these complex proteomics patterns, reflecting
both increases and decreases in specific serum proteins/
peptides, underscores the power of this technology in the
development of new diagnostic methods to detect early
cancer.
Both classification models greatly improve the sensitivity
and specificity of the current principal biomarker used for
PCa, CA19-9. Due to the low prevalence of PCa, however, a
much greater sensitivity is required before these types of
approaches can be clinically useful for the early detection of
PCa in an asymptomatic population. The predictive value
of the mass peaks identified in this study requires further
testing, including the examination of a larger panel of serum
from patients with stage I disease, other malignancies, as
well as benign diseases (including pancreatitis to assure that
we are not merely identifying acute-phase proteins associ-
ated with inflammation in cancer). Thus, although our results
are very promising, they are not intended to be the final
diagnostic paradigm.
In addition, protein discriminators may be added to these
models after analysis of protein profiles produced from other
serum fractions from these patients, as well as evaluation on
other chip surfaces. For example, by combining the spectral
data obtained from both weak cation exchange and copper
metal affinity capture arrays, Ban˜ez et al. [31] reported a
significant enhancement in classification accuracy in their
study of prostate cancer. Such studies are ongoing with our
cohort. During the preparation of this report, a paper was
recently published describing a similar diagnostic approach
for PCa [34]. These authors also analyzed protein profiles
from two ProteinChip surfaces (including the IMAC sur-
face used in this study) as well as immunologic detection
of CA19-9. Improvements in diagnostic accuracy were also
noted for combinations between a particular marker panel
derived from one SELDI surface and CA19-9; however,
diagnostic panels were not reported for combinations of
markers between chip surfaces or anion exchange fractions.
Using a unified maximum separability algorithm to identify a
discriminatory panel of markers to differentiate sera of PCa
patients from control subjects, Koopmann et al. [34]
achieved a maximum sensitivity and specificity of 78% and
97%, respectively, using two protein peaks identified from
theWCX surface. The most discriminating peaks identified in
fraction 1 from the anion exchange resin applied to the IMAC
surface in their study, however, produced less effective
results. Interestingly, using a similar fractionation strategy
and ProteinChip IMAC surface, we have identified panels of
four or five markers using either multivariate logistic regres-
sion or CART models that yielded 100% sensitivity and
93.5% to 100% specificity.
Besides the apparent difference in data analysis techni-
ques utilized in these two studies, we attempted to identify
other differences that may explain the disparity in our abilities
to discriminate the PCa versus normal patient sera, particu-
larly when comparing the same protein fractionation scheme
and ProteinChip surface. Because both studies used ap-
proximately the same sample sizes to compare PCa versus
healthy controls, we examined other differences between the
patient populations. Both studies included patients with other
pathologic conditions (e.g., inflammatory diseases) as con-
trols to mute the identification of proteins involved merely in
inflammatory responses, although our study did not include a
patient population specifically for nonmalignant pancre-
atic diseases. However, this does not account for the dis-
criminatory differences observed for PCa versus healthy
individuals.
Although the mean age of PCa patients closely paralleled
those used in the Koopmann study [34], we noted that the
mean age of our control group was significantly lower. To
examine the possible effects of using a control population
with a lower mean age, we divided our control samples
(mean age ± SD) into a young group (41.7 ± 9.3) and an
old group (67.3 ± 8.8) such that the mean age of the old
group was similar to the cancer group. A comparison be-
tween the median peak intensities for the young and old
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groups did not reveal any significant differences for any of
the eight classification peaks (data not shown). Thus, the
difference in mean age of our normal and cancer groups
does not appear to have influenced our classification results.
Other potential causes of the differences observed in these
two studies include variations in the procedures used in
collecting and handling serum specimens, differences in
the alignment and calibration of the mass spectrometers,
or lot variations in the preparation of the ProteinChip surfa-
ces. It is intriguing, however, that with all the numerous
factors that might explain the differences in our results, in
both of our studies, one of the most discriminating markers
identified from the IMAC profiles is the peak with m/z 3967
(reported as 3966.8 in our study). This peak was utilized as a
discriminator in our multivariate logistic regression model
(Table 2) and as the first decision node in the classification
tree (Figure 5). In fact, this peak was incorporated into 93%
of multivariate logistic regression models developed under
forward selection (Figure 3), and was the major determinant
for segregating 79% of the PCa specimens in the CART
model (Figure 5, terminal node 1). Similarly, this peak was
among the discriminators in the three-peak IMAC-Cu2+
panel described by Koopmann et al. [34]. With such a similar
finding, it is tempting to speculate that we have both inde-
pendently identified the same serum protein in our two
studies. Thus, rather than highlighting the differences
obtained in these studies using this technology, this obser-
vation strengthens the notion that SELDI protein profiling is a
robust, reproducible procedure. The other two discriminators
in their three-peak panel (3885 and 8929) are within approx-
imately 17 and 23 Da of peaks we have identified (3902.2
and 8951.7); however, these would represent rather large
deviations by mass spectrometry. In view of the 3967 peaks
with essentially the same m/z in these two reports, it is
questionable whether these peaks represent the same
protein. These results, however, thus support the need
to identify these proteins to substantiate these evocative
findings.
The logistic regression classification equation (Table 2)
and classification tree (Figure 5) described in this report
should provide an easy means for validating future SELDI
analyses performed in any laboratory using the same Pro-
teinChip surface. After further validation and refinements to
the classification models, proteomics fingerprints may direct-
ly aid in the diagnosis of PCa and other malignancies and,
in themselves, constitute a valuable resource. The iden-
tification of the protein components of these fingerprints,
however, will also provide important insights into the mi-
croenvironment of tumors and provide a better understand-
ing of the processes involved in tumor development and
growth.
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ERRATUM
Chromosomal Alterations during Lymphatic and Liver
Metastasis Formation of Colorectal Cancer
Thomas Kno¨sel, Karsten Schlu¨ns, Ulrike Stein, Holger Schwabe, Peter Michael Schlag, Manfred Dietel
and Iver Petersen
The image in Figure 1A of the article by Kno¨sel et al. (Neoplasia, Vol. 6, No. 1, January/February 2004, pp. 23–28) is
incorrect. It shows the CGH results of a subgroup of only 54 colorectal carcinomas and not the entire collective of
63 tumors as mentioned in the text. The larger collective shows slightly different frequencies of chromosomal imbalances
for single chromosomes (e.g., a maximal 90% incidence of gains on chromosome 20q). The correct image as well as
the histograms and CGH profiles of all individual tumors are accessible at the Charite´ CGH online tumor database at
http://amba.charite´.de/cgh.
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